利尿剂和减少发生透析患者的死亡率:为期两年的观察性研究
Maxime Ingwiller1, Dogan-Firat Bozman1, Nans Florens1
1Department of Nephrology, Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, 67 000, Strasbourg, France.
Scientific reports
|November 10, 2024
概括
利尿剂可能会降低透析患者的死亡率,但长期使用 (≥80%) 会增加死亡率和住院风险. 这表明潜在的残留利尿症有助于流体过载.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 流体过载是透析患者发病率和死亡率的重要预测因素.
- 利尿剂对发生性透析患者的死亡率和住院率的影响尚不清楚.
研究的目的:
- 调查循环利尿剂暴露与在开始透析后的前两年死亡率和住院率之间的关联.
- 为了确定不同时间使用利尿剂是否会影响患者的治疗结果.
主要方法:
- 从REIN注册表中分析了2009-2015年间开始透析的成年患者.
- 根据循环利尿剂暴露 (<5%,5-50%,50-80%,≥80%) 患者被分为四组.
- 逆概率加权 (IPW) 倾向得分分析被用于调整混因素.
主要成果:
- 与没有暴露 (37.5%) 相比,尿剂暴露与显著较低的两年死亡率 (24.8%) 相关.
- 然而,最高的死亡率 (68.2%) 发生在≥80%暴露的组中,这表明了U形的关联.
- 随着长时间的利尿剂暴露 (≥80%),人们观察到更多的住院和更长的住院时间.
结论:
- 虽然利尿剂的使用通常与透析患者的死亡率降低有关,但长期暴露 (≥80%) 与死亡率和住院治疗增加有关.
- 这表明,大量的利尿剂使用可能代表剩余的利尿症,可能掩盖或加剧慢性液体过载.
相关概念视频
Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Dialysis
269
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
269
Antihypertensive Drugs: Action of Diuretics
623
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
623
Antihypertensive Drugs: Thiazide-Class Diuretics
546
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
546
Antihypertensive Drugs: Potassium-Sparing Diuretics
461
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
461
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391


